Drug Approval | September 01, 2024
Biocon Pharma receives USFDA approval for daptomycin
The approval further adds to Biocon’s portfolio of complex drug products
The approval further adds to Biocon’s portfolio of complex drug products
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
TABRECTA is the brand of Novartis. Natco believes it is the first company to have filed a substantially-complete ANDA
First-in-human Phase-1 study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SUVN-I6107 in healthy subjects
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
The partnership will provide health plans with an out-of-the-box compliance solution for CMS-9115 and CMS-0057 rules
Brimonidine Tartrate Ophthalmic Solution, 0.1% is an alpha adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
Bortezomib Injection is approved for subcutaneous or intravenous use. It is available as a single dose vial of 3.5 mg/1.4 mL (2.5 mg/mL)
Subscribe To Our Newsletter & Stay Updated
